NextCure NXTC
NASDAQ NXTC
$5.70 +0.26 (+4.79%)
As of: Oct 21, 2026 · 10:26 AM EDT

NextCure (NXTC) EBIT Margin (2019 - 2020)

Updated

NextCure's EBIT Margin came in at -184.22% for FY2020, up 406.33 percentage points from -590.55% in FY2019.

Analysis

NextCure (NXTC) EBIT Margin (2019 - 2020) Analysis & Trends

  • Per Business Quant, earlier years put EBIT Margin at -590.55% in FY2019.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBIT Margin (Qtr)
1 Eli Lilly 1,132.04 Bn 1,100.62 Bn 19.71 Bn 51.16%
2 Johnson & Johnson 614.86 Bn 533.39 Bn 17.26 Bn 28.21%
3 AbbVie 503.32 Bn 476.44 Bn 12.70 Bn 37.86%
4 Merck 367.14 Bn 321.52 Bn 12.21 Bn -3.52%
5 Novartis Ag 297.85 Bn 261.84 Bn 11.24 Bn 32.97%
6 Astrazeneca 261.69 Bn 235.37 Bn 12.86 Bn 20.57%
7 Amgen 236.43 Bn 191.82 Bn 7.24 Bn 34.95%
8 Gilead Sciences 190.71 Bn 164.90 Bn 6.22 Bn -133.21%
9 Pfizer 170.03 Bn 116.68 Bn 10.94 Bn 28.37%
10 NextCure 30.27 Mn -90.49 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2020 36.70%
Dec 31, 2019 -599.00%
Sep 30, 2019 -612.89%
Jun 30, 2019 -638.73%
Mar 31, 2019 -502.21%
API Access

NextCure EBIT Margin API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=ebit-margin&ticker=NXTC&period=max&api_key=YOUR_API_KEY